Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00DHM
|
||||
| Former ID |
DIB015188
|
||||
| Drug Name |
SDZ-208911
|
||||
| Synonyms |
SDZ-HAC-911; N-[(8alpha)-2,6-Dimethylergolin-8-yl]-2,2-dimethylpropanamide; N-(5,7-Dimethyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[4,3-fg]quinolin-9alpha-yl)-2,2-dimethylpropanamide; 2,6-Dimethyl-8alpha-(2,2-dimethyl-1-oxopropylamino)ergoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] | Investigative | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H29N3O
|
||||
| Canonical SMILES |
CC1=C2CC3C(CC(CN3C)NC(=O)C(C)(C)C)C4=C2C(=CC=C4)N1
|
||||
| InChI |
1S/C21H29N3O/c1-12-15-10-18-16(14-7-6-8-17(22-12)19(14)15)9-13(11-24(18)5)23-20(25)21(2,3)4/h6-8,13,16,18,22H,9-11H2,1-5H3,(H,23,25)
|
||||
| InChIKey |
ZNMWUMGOSWLWOH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 101000-37-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Modulator | [1], [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.